Diferencia entre revisiones de «Quinidine»
(Created page with "==Background== *Inexpensive with restricted indications, causing it to be inaccessible in many areas globally *Main manufacturer halted production in 2010<ref>Olsson G.; To t...") |
Sin resumen de edición |
||
| Línea 10: | Línea 10: | ||
==Sources== | ==Sources== | ||
</ | <references/> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
Revisión del 20:37 5 ago 2016
Background
- Inexpensive with restricted indications, causing it to be inaccessible in many areas globally
- Main manufacturer halted production in 2010[1]
- Historically both supraventricular tachydysrhytmia, ventricular dysrhythmia, malaria treatment, many other first-line therapies have replaced its use
- An effective treatment and prevention strategy for[2]:
- Brugada syndrome arrhythmic electrical storm
- Idiopathic ventricular fibrillation
- Early repolarization syndrome (though NOT benign, see benign early repolarization)
- Congenital short QT syndrome